ERBB2 and breast carcinoma: Since the publication by O’Brien et al. in 2010 [5], a number of other studies have validated their finding, identifying higher mortality in Black compared to White women with HR+/HER2-breast cancer (Table 1) [4,6,8,9,10,11,12,13,14,15,16].